These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 7169121)

  • 1. [Sézary syndrome: treatment with a prednisolone-chlorambucil combination].
    Lorent A; Feermans W; Blondeel A; Meerts P; Achten G
    Dermatologica; 1982 Nov; 165(5):464-5. PubMed ID: 7169121
    [No Abstract]   [Full Text] [Related]  

  • 2. Intermittent leukapheresis: an adjunct to low-dose chemotherapy for Sézary syndrome.
    McEvoy MT; Zelickson BD; Pineda AA; Winkelmann RK
    Acta Derm Venereol; 1989; 69(1):73-6. PubMed ID: 2563614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sézary syndrome among the cases at the Warsaw Dermatological Hospital].
    Kalbarczyk K; Bujakiewicz A; Fiedorowicz M
    Przegl Dermatol; 1985; 72(6):527-35. PubMed ID: 3832161
    [No Abstract]   [Full Text] [Related]  

  • 4. [Extracorporeal photopheresis in the therapy of Sézary syndrome].
    Marschalkó M; Knobler R; Soós G; Berecz M; Pálóczy K; Rácz I
    Orv Hetil; 1993 Jun; 134(23):1253-7. PubMed ID: 8332344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sézary-type cutaneous T-cell leukaemia. Response to Winkelmann regimen.
    Harland CC; Balsitis M; Millard LG
    Acta Derm Venereol; 1990; 70(3):251-3. PubMed ID: 1972843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combined leukeran-prednisolone therapy in metastasizing breast cancer].
    Cziráki L; Oó M
    Fortschr Med; 1977 Apr; 95(15):1043-6. PubMed ID: 858580
    [No Abstract]   [Full Text] [Related]  

  • 7. [Sezary's syndrome. Clinical, hematological and evolutive aspects].
    Crespo V; Ramírez G; Lendoyro A
    Actas Dermosifiliogr; 1978; 69(7-8):197-208. PubMed ID: 717080
    [No Abstract]   [Full Text] [Related]  

  • 8. [Indications and effectiveness of combined therapy in chronic glomerulonephritis].
    Ratner MIa; Biriukova LS; Makurov AI
    Ter Arkh; 1987; 59(8):29-34. PubMed ID: 3686442
    [No Abstract]   [Full Text] [Related]  

  • 9. The treatment of Sézary syndrome.
    Winkelmann RK; Diaz-Perez JL; Buechner SA
    J Am Acad Dermatol; 1984 Jun; 10(6):1000-4. PubMed ID: 6736317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
    Brennand S; Sutton VR; Biagi J; Trapani JA; Westerman D; McCormack CJ; Seymour JF; Kennedy G; Prince HM
    Br J Dermatol; 2005 Jun; 152(6):1199-205. PubMed ID: 15948982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bexarotene combination therapy for patients with Sézary syndrome.
    Ranki A
    Dermatol Clin; 2008 Jan; 26 Suppl 1():55-7. PubMed ID: 18405189
    [No Abstract]   [Full Text] [Related]  

  • 12. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.
    el-Azhary RA; Bouwhuis SA
    Int J Dermatol; 2005 Jan; 44(1):25-8. PubMed ID: 15663654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hemoperfusion through activated charcoal in the complex treatment of systemic lupus erythematosus].
    Nasonova VA; Ivanova MM; Speranskiĭ AI; Solov'ev SK; Shumakov VI
    Ter Arkh; 1981; 53(8):107-12. PubMed ID: 7292329
    [No Abstract]   [Full Text] [Related]  

  • 14. Follicular hyperkeratosis as a manifestation of Sézary syndrome.
    Al-Niaimi F; Cox NH; Taylor WD
    Br J Dermatol; 2010 Mar; 162(3):695-6. PubMed ID: 20030643
    [No Abstract]   [Full Text] [Related]  

  • 15. The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome.
    McGinnis KS; Ubriani R; Newton S; Junkins-Hopkins JM; Vittorio CC; Kim EJ; Wysocka M; Rook AH
    Arch Dermatol; 2005 Sep; 141(9):1176-8. PubMed ID: 16172331
    [No Abstract]   [Full Text] [Related]  

  • 16. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome.
    Tsirigotis P; Pappa V; Papageorgiou S; Kapsimali V; Giannopoulou V; Kaitsa I; Girkas K; Papageorgiou E; Stavrianeas N; Economopoulos T; Dervenoulas J
    Br J Dermatol; 2007 Jun; 156(6):1379-81. PubMed ID: 17459033
    [No Abstract]   [Full Text] [Related]  

  • 17. [Sézary syndrome showing a stable clinical course for more than four years after oral administration of etoposide and methotrexate].
    Hirayama Y; Nagai T; Ohta H; Koyama R; Matsunaga T; Sakamaki S; Niitsu Y
    Rinsho Ketsueki; 2000 Sep; 41(9):750-4. PubMed ID: 11070938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The therapy of mesangiocapillary glomerulonephritis].
    Ratner MIa; Fedorova ND; Biriukova LS; Makurov AI
    Ter Arkh; 1995; 67(8):10-2. PubMed ID: 7482319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome.
    Gardner JM; Introcaso CE; Nasta SD; Kim EJ; Vittorio CC; Rook AH
    J Am Acad Dermatol; 2009 Jul; 61(1):112-6. PubMed ID: 19539845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental study of the combined effect of leukeran, degranol and predisolone.
    Stukov AN
    Neoplasma; 1975; 22(2):181-4. PubMed ID: 1161113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.